Area of research
Cancer Research · Emergency Medical Services
Research interest
Research interests include Breast Cancer Treatment Studies, Central Venous Catheters and Hemodialysis, MicroRNA in disease regulation, and Cardiac Arrhythmias and Treatments.
Clinical efficacy and therapy response prediction of neoadjuvant dalpiciclib plus letrozole in postmenopausal patients with HR+/HER2- stage II-III breast cancer (DARLING 01): a single-arm, open-label, exploratory study
Artesunate regulates malignant progression of breast cancer cells via lncRNA TUG1/miR-145-5p/HOXA5 axis
Catheter-related right atrial thrombosis from malpositioned totally implantable venous access ports: Case series and preventive lessons
Overall survival and disease‐free survival prediction in Chinese women with breast cancer aged 70 years or older by using nomograms
Abstract PO2-02-05: CDK4/6 inhibitor dalpiciclib combined with letrozole as neoadjuvant therapy in postmenopausal patients with hormone receptor-positive, HER2-negative stage II-III breast cancer: a single-arm exploratory trial
Exploring risk factors for totally implantable venous access devices (TIVADs)-related thrombotic occlusion in the off-treatment period
Clinical practice guidelines for the diagnosis and treatment of inflammatory breast cancer: Chinese Society of Breast Surgery (CSBrS) Practice Guidelines 2022
Pregnancy-associated breast cancer (PABC) in young women: a matched case-control study
Circ_0,007,331 Promotes the PTX Resistance and Progression of Breast Cancer via miR-200b-3p/ANLN
A randomized trial of pegylated recombinant human granulocyte-colony stimulating factor to prevent febrile neutropenia in breast cancer after chemotherapy.
Exosome <scp>miR</scp>‐134‐5p restrains breast cancer progression via regulating <scp>PI3K</scp>/<scp>AKT</scp> pathway by targeting <scp>ARHGAP1</scp>
Systemic thrombolysis and anticoagulation therapy for catheter-related right atrial thrombosis caused by TIVAP: A case report and review of the literature
Clinical practice guidelines for breast cancer implantable intravenous infusion ports: Chinese Society of Breast Surgery practice guidelines 2021
Nurse Versus Clinician Symptomatic Adverse Events Assessment Based on Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE): Results of a Questionnaire-Based Study
Comparison of Two Methods of Removing Totally Implantable Vascular Access Devices- A Single-Center Experience
Clinicians versus patients subjective adverse events assessment: based on patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
Prognostic Value of LRG1 in Breast Cancer: A Retrospective Study
[Endocrine therapy for breast cancer: past and present].
PubMed 2015cited by 4position: first